Malignant Ascites Therapeutics Market Size in the 7MM was ~ USD 1990 Million in 2020, is expected to grow by 2034, and estimated DelveInsight

Posted on
by

Malignant Ascites Therapeutics Market Size in the 7MM was ~ USD 1990 Million in 2020, is expected to grow by 2034, and estimated DelveInsight

DelveInsight’s “Malignant Ascites Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Malignant Ascites, historical and forecasted epidemiology as well as the Malignant Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Discover Key Insights into the Malignant Ascites Market with DelveInsight’s In-Depth Report @ Malignant Ascites Market Size

 

Key Takeaways from the Malignant Ascites Market Report

  • Among the 7MM, the United States accounted for the highest incident cases of Malignant ascites in 2020, with around 350,000 cases; these cases are expected to increase during the forecast period.
  • Among all the associated cancers, the highest incident cases were reported in Breast Cancer. In 2020 the total incident cases of Breast Cancer were 640,000.
  • In 2020, the total patient pool of Malignant Ascites were 390,000 in the EU4 and the UK.
  • The leading Malignant Ascites Companies such as Clover Biopharmaceuticals, Wuhan YZY Biopharma Co., Ltd., Neovii Biotech, Jiangsu Simcere Pharmaceutical, Neovii Biotech, Sanofi, and others
  • Promising Malignant Ascites Therapies such as SCB-313, M701, catumaxomab, Endostar, Catumaxomab, aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), and others

 

Navigate the complexities of the Malignant Ascites Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Malignant Ascites Market Forecast. Click here to get more insights @ Malignant Ascites Treatment Market

 

Malignant Ascites Epidemiology Segmentation in the 7MM

  • Total Incident Cases of Ascites in Selected Indications (Ovarian, Colorectal, Gastric, and Others) in the 7MM
  • Incident Cases of Malignant Ascites in Selected Indications in the 7MM
  • Total Treated Cases of Malignant Ascites in the 7MM

 

Download the report to understand which factors are driving Malignant Ascites epidemiology trends @ Malignant Ascites Prevalence

 

Malignant ascites Emerging Drugs Profile

  • Catumaxomab: Lindis Biotech

Catumaxomab is a bispecific trifunctional antibody that binds directly to the tumor cell with one of its binding sites. It activates two essential components of the immune system with the other binding sites: T cells and macrophages (scavenger cells). The antibody recognizes and binds to all EpCAM-positive tumor cells, including critical cancer stem cells and all CD3-positive T cells. The EpCAM marker is present on almost all carcinomas and is, therefore, a promising approach for targeted cancer treatment. As per company pipeline, catumaxomab is in the preregistration stage of development for the treatment of Malignant ascites.

 

  • M 701: Wuhan YZY Biopharma

M701 is a new biological Class I drug that targets both EpCAM and CD3 being developed by YBODY Biotech through its independently patented asymmetric bispecific antibody YBODY® platform. The drug is mainly used for the treatment of malignant ascites (MA) and malignant pleural effusion (MPE) derived from EpCAM-positive cancer.M701 dual-antibody targets the EpCAM antigen on one end. At the same time, the CD3 antibody on the other end can bridge T cells and activate T cells to kill EpCAM-positive tumor cells. Currently, M701 is in the Phase II stage of development for the treatment of malignant ascites.

 

Malignant Ascites Drugs Market Insights

Antibody-dependent cell cytotoxicity

Antibody-Dependent Cellular Cytotoxicity (ADCC) is a crucial mechanism of the immune system involving the targeting and destruction of pathogenic cells by effector cells, particularly natural killer (NK) cells. ADCC is a process where specific antibodies bind to pathogens, marking them for destruction by NK cells through the injection of cytotoxic factors, leading to cell lysis. Antibodies recognize and bind to target cells, which are then attacked and destroyed by effector cells like NK cells. This process plays a vital role in immune responses against pathogens and cancer cells.

 

Get In-Depth Knowledge on Malignant Ascites Market Trends and Forecasts with DelveInsight @ Malignant Ascites Treatment Market

 

Malignant Ascites Therapies and Companies

  • SCB-313: Clover Biopharmaceuticals
  • M701: Wuhan YZY Biopharma Co., Ltd.
  • catumaxomab: Neovii Biotech
  • Endostar: Jiangsu Simcere Pharmaceutical
  • Catumaxomab: Neovii Biotech
  • aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®): Sanofi

 

Scope of the Malignant Ascites Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM
  • Malignant Ascites Companies: Clover Biopharmaceuticals, Wuhan YZY Biopharma Co., Ltd., Neovii Biotech, Jiangsu Simcere Pharmaceutical, Neovii Biotech, Sanofi, and others
  • Malignant Ascites Therapies: SCB-313, M701, catumaxomab, Endostar, Catumaxomab, aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), and others
  • Malignant Ascites Therapeutic Assessment: Malignant Ascites current marketed and Malignant Ascites emerging therapies
  • Malignant Ascites Market Dynamics: Malignant Ascites market drivers and Malignant Ascites market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Malignant Ascites Unmet Needs, KOL’s views, Analyst’s views, Malignant Ascites Market Access and Reimbursement

 

Gain a strategic edge in the Malignant Ascites Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Malignant Ascites Market Forecast. Click here to lead in advancements @ Malignant Ascites Clinical Trials Assessment

 

Table of Contents

1. Malignant Ascites Market Report Introduction

2. Executive Summary for Malignant Ascites

3. SWOT analysis of Malignant Ascites

4. Malignant Ascites Patient Share (%) Overview at a Glance

5. Malignant Ascites Market Overview at a Glance

6. Malignant Ascites Disease Background and Overview

7. Malignant Ascites Epidemiology and Patient Population

8. Country-Specific Patient Population of Malignant Ascites

9. Malignant Ascites Current Treatment and Medical Practices

10. Malignant Ascites Unmet Needs

11. Malignant Ascites Emerging Therapies

12. Malignant Ascites Market Outlook

13. Country-Wise Malignant Ascites Market Analysis (2020–2034)

14. Malignant Ascites Market Access and Reimbursement of Therapies

15. Malignant Ascites Market Drivers

16. Malignant Ascites Market Barriers

17. Malignant Ascites Appendix

18. Malignant Ascites Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage